(Q43569399)

24 November 2017

title

Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance (English)

1 reference

24 November 2017

1 reference

1 reference

5

Masashi Mizokami

1 reference

24 November 2017

9

Kazuaki Chayama

1 reference

24 November 2017

10

Michio Imamura

1 reference

24 November 2017

3

Fumitaka Suzuki

1 reference

24 November 2017

4

Mariko Kobayashi

1 reference

24 November 2017

6

Yasuhito Tanaka

1 reference

24 November 2017

1

Eiji Tanaka

1 reference

24 November 2017

11

Hiroshi Yatsuhashi

1 reference

24 November 2017

14

Sumio Kawata

1 reference

24 November 2017

7

Takeshi Okanoue

1 reference

24 November 2017

13

Hiroshi Yotsuyanagi

1 reference

24 November 2017

8

Masahito Minami

1 reference

24 November 2017

Akihiro Matsumoto

2

1 reference

24 November 2017

Shinya Nagaoka

12

1 reference

24 November 2017

Tatsuji Kimura

15

1 reference

24 November 2017

Noboru Maki

16

1 reference

24 November 2017

Shiro Iino

17

1 reference

24 November 2017

Kendo Kiyosawa

18

1 reference

24 November 2017

HBV Core-Related Antigen Study Group

19

1 reference

24 November 2017

publication date

1 February 2006

1 reference

24 November 2017

1 reference

24 November 2017

volume

26

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

90-96

1 reference

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Experimental transmission of duck hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Long-term therapy of chronic hepatitis B with lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

Response predictors and results of a long-term treatment with lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01200.X

10.1111/J.1478-3231.2005.01200.X

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference